



alzchem
group

AGILE SCIENCE PURE RESULTS

alzchem
group



Q4

2022

ANDREAS NIEDERMAIER, CEO
DR. GEORG WEICHSELBAUMER, CSO

FEB 28, 2022

DISCLAIMER

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements about the business, financial condition and earnings performance of the Alzchem Group. These statements are based on assumptions and projections resting upon currently available information and present estimates. They are subject to a multitude of uncertainties and risks. Actual business development may therefore differ materially from what has been expected. Beyond disclosure requirements stipulated by law, Alzchem does not undertake any obligation to update forward-looking statements.

Unless stipulated otherwise, all values are rounded up or down in accordance with the commercial rounding practices. Please note that differences can result from the use of rounded amounts and percentages.

AGENDA – ANALYST PRESENTATION Q4 2022

- I. **Executive Summary**
- II. Business and financial details
- III. Back-Up

HIGHLIGHTS

Challenging but – under the circumstances – successful year 2022



Sales 2022 at record level due to successful cost forwarding policy



EBITDA slightly below previous year level due to volatile power prices, but within the forecasted corridor



Whole year strongly impacted by negative effects on raw material, electricity and logistic prices due to the crisis



Ongoing strong demand in human nutrition, steel and pharma as well as automotive industry



High-growth segment Specialty Chemicals not only due to price increase, but also because of higher demand



Successful launch of expanded Creapure® and Natriumsarkosinat production in Nov 2022

IMPLEMENTING OPERATING TARGETS

Focus on the key growth drivers and sustainability



Implementation of price increases, at least in the amount of the cost increases

realized

SUSTAINABILITY

on the way

- Set the path to CO₂ neutral growth and climate neutrality by 2045
- Vision 0 accidents
- Vision 0 waste – promoting circular economy
- Introduction of EU Taxonomy Regulation – Taxonomy compliance
- Organize transition from NFRD (Nonfinancial Reporting Directive) to CSRD (Corporate sustainability Reporting Directive)

Realization and commissioning of Creapure® capacity expansion

realized

Continue to grow NITRALZ® and Creamino® business


on the way

Management of COVID-19 effects

realized

TURBULENT MARKET ENVIRONMENT – CURRENT DEVELOPMENT

Energy costs facing all time high in Q3/2022



COMMENTS

- Due to the Ukraine war, the peak of electricity prices was reached in Q3/22 (~ 110% above Q4/21)
- Slight reduction of electricity prices in Q4/2022 due to Christmas holidays and decreasing energy prices, but still on a persistent high level
- Alzchem reacted to this development by making use of its flexibility in managing production



This enabled us to prevent the extreme electricity price developments being fully reflected in the figures

Source: EPEX-SPOT Baseload Day Ahead daily average

FINANCIAL OVERVIEW

Sales growth with strong cost pressure in 2022



Alzchem Group	Q4 2021	Q4 2022	yoy %	2021 1 - 12	2022 1 - 12	yoy %
SALES (in M€)	111.1	133.2	+19.9%	422.3	542.2	+28.4%
EBITDA (in M€)	12.5	14.4	+15.4%	62.0	61.4	-1.0%
EBITDA margin (in %)	11.2%	10.8%	-0.4pp	14.7%	11.3%	-3.4pp
Earnings per Share (in €)	0.58	0.67	+15.5%	2.72	2.96	+8.8%

- Challenging environment throughout the year driven by the Ukraine war as well as Covid
- Highly volatile and tense electricity, raw material and logistic situation negatively burdened the EBITDA
- Nevertheless, sales on historical record level due to successful cost forwarding policy
- Positive sales development driven equally by both operating segments, Basics & Intermediates as well as Specialty Chemicals
- Specialty Chemicals segment still on promising growth course, especially within the human nutrition sector

SALES ANALYSIS	DELTA Q4	DELTA 01 - 12
Volume	-8.2%	-2.6%
Price	24.2%	27.6%
Currency	3.9%	3.4%

AGENDA – ANALYST PRESENTATION Q4 2022

- I. Executive Summary
- II. Business and financial details**
- III. Back-Up



NITRALZ®

Perlka®
CALCIUM CYANAMIDE

CaD

BASICS & INTERMEDIATES


The "Basics & Intermediates" segment comprises the production of basic and intermediate products that are marketed as independent products for example in agriculture, steel production and the automotive sector and as raw materials for the manufacture of specialty chemicals.

BASICS & INTERMEDIATES SEGMENT (in M€)




Sales significantly above prior year but cost pressure on EBITDA


SALES




EBITDA



SALES



EBITDA



SALES ANALYSIS

	DELTA Q4	DELTA 01 - 12
Volume	- 27.8%	- 12.3%
Price	+ 37.6%	+ 40.6%
Currency	+ 0.8%	+ 0.8%

COMMENTS

- Q4/2022 sales ~11% above previous year's level
- Sales within the metallurgic and pharmaceutical sector (DCD) significantly above Q4/2021
- Weaker sales performance within the agriculture sector (Perlka®) in Q4/2022
- Impact from price increases overcompensates quantity decrease
- Slight reduction of energy and raw material markets visible in Q4/2022, but still on a very high level compared to 2021
- Thus, EBITDA-Margin of 7.4% in Q4/2022 (previous year +2.6%)



CREAMINO

Dormex[®]

Bioselect[®]

DYHARD[®]

Creapure[®]

SPECIALTY CHEMICALS


The "Specialty Chemicals" segment produces and sells high-quality growth products in the area of specialty chemicals.

SPECIALTY CHEMICALS SEGMENT (in M€)


High growth delivered despite challenging environment




SALES



EBITDA



SALES



EBITDA



SALES ANALYSIS

	DELTA Q4	DELTA 01 - 12
Volume	+ 6.6%	+ 4.8%
Price	+ 15.5%	+ 20.0%
Currency	+ 6.9%	+ 5.9%

COMMENTS

- Sales in Q4/2022 ~ 29% higher than in Q4/2021
- Demand for building blocks, automotive sector (Nitroguanadine, DYHARD®) as well as agriculture sector (Cyanamide, Dormex®) on a persistent high level
- Successful strategic realignment in the nutritional supplements sector (Creapure®)
- High cost pressure has a negative impact on the EBITDA-Margin in Q4/2022 (10.5% vs. previous year 20.6%)



OTHER & HOLDING


The "Other & Holding" segment offers infrastructure and energy supply services at our locations for the chemicals segments and for external customers.

OTHER & HOLDING SEGMENT (in M€)


Development of services is quite robust




SALES




EBITDA



SALES



EBITDA



SALES ANALYSIS

	DELTA Q4	DELTA 01 - 12
Volume	+ 5.0%	+ 0.5%
Price	+ 2.6%	+ 2.6%
Currency	± 0.0%	± 0.0%

COMMENTS


- Q4/2022 Sales ~8% above previous year's level
- Sales performance supported by higher demand for energy supply and infrastructure service

BALANCE SHEET (in M€)

Increase of balance sheet total and equity ratio




ASSETS



- Assets increased by 45.2 M€ compared to previous year
- Decrease in non-current assets driven by reduction in deferred taxes for pension provision (higher interest rate for pension valuation)
- Working capital increased – Inventory intensity developed from 20.5% to 22.6%. Price for raw materials and energy as well as availability effects are the reason for inventory increase and inventory safeguards. Trade receivables followed higher sales and increased by 14.9 M€.


LIABILITIES



- Group equity ratio improved to 34.5% (2021: 23.7%) due to three effects.
 - + positive result of 30.2 M€
 - dividend payment of 10.1 M€ in May 2022
 - + increase OCI (development of interest rate for pension provision from 1.0% to 3.7%)
- Non-current liabilities decreased mainly due to lower pension provision (interest impact)
- Current liabilities increased significantly to finance working capital needs

CASHFLOW (in M€)

Net cash flow strongly impacted by NWC management



- Even though net result is higher than last year, net cash flow is much lower than prior period (reduction by 47.2 M€). Main impact was the increase in payments for net working capital (increase by 43.2 M€) for building inventory safety stock.
- Investing cash flow on prior year level (28.5 M€). Major single investment was expansion of Creapure® capacity (13.3 M€). Investment for renewal of power supply infrastructure amounted to 3.8 M€.
- Financing cash flow impacted by financing of net working capital with cash inflows of 56.3 M€ from short term borrowings. While regular loan and lease repayments were slightly below prior year (-2.2 M€), dividend payments were higher than last year (+2.3 M€).

IMPLEMENTING OPERATING TARGETS

Focus on the key growth drivers and sustainability



IMPROVEMENT

- Raw material price increases at least passed on to the market
- Flexibilization of production
- Reduce waste via development of new processes

GROWTH

- Volume growth and full utilization of realized capex (Creapure®, Creamino®, Nitralz®, SiliconNitride)
- Establish Eminex® as a methane prevention product
- Initiate and decide on capacity expansion of MultiPurpose plants

SUSTAINABILITY


- Vision 0 accidents and 0 waste
- Implementation of climate roadmap (with reduction of CO₂ and water footprint (-10%))
- Implement EU Taxonomy Regulation and CSRD in an audit-ready manner

OUTLOOK 2023 (in M€)


Positive sales and EBITDA development forecasted for 2023



SALES



EBITDA



COMMENTS

- The Outlook is based on the following assumptions:
 - No occurrence of a global recession
 - EUR/US dollar exchange rate of USD 1.05
 - Costs for raw materials and logistics remain at the high level of 2022 with a slight downward trend. Electricity remains at the high average level of 2022
 - No change in existing product registrations, new registrations applied for to be granted
 - Availability of raw materials and logistics
 - Ukraine war does not deliver further interruptions
- Segment Specialty Chemicals expected to promote the positive sales and EBITDA development, mainly by human nutrition as well as animal nutrition business growth
- Stable price development on previous year's level expected

FINANCIAL CALENDAR*

Upcoming dates



MAY 4	2023	Quarterly Statement 1st Quarter 2023
MAY 11	2023	Annual General Meeting 2023
MAY 16	2023	Frühjahrskonferenz 2023
AUG 3	2023	Half-Year Financial Report 2023
SEP 18 – 20	2023	Berenberg and Goldman Sachs German Corporate Conference 2023
SEP 18 – 23	2023	Baader Investment Conference 2023
OCT 26	2023	Quarterly Statement 3rd Quarter 2023
NOV 15	2023	Münchner Kapitalmarkt Konferenz 2023
NOV 27 – 29	2023	Deutsches Eigenkapitalforum 2023

*subject to change

**AGILE SCIENCE
PURE RESULTS**

**alzchem
group**



Investor Relations

T +49 8621 86-2888

F +49 8621 86-502888

ir@alzchem.com

AGENDA – ANALYST PRESENTATION Q4 2022

- I. Executive Summary
- II. Business and financial details
- III. Back-Up**

BALANCE SHEET

Alzchem Group




ALZCHEM GROUP (IN T€)	31.12.2021	31.12.2022	Deviation	
Intangible assets	2,329	2,954	625	26.8%
Tangible assets	178,806	181,526	2,720	1.5%
Investment properties				
Right of use (assets)	7,686	6,250	-1,436	-18.7%
Investments accounted for using the equity				
Financials assets	20	6	-15	-73.1%
Trade receivables				
Other receivables	1,320	1,531	211	16.0%
<i>there of Deferred tax assets for pensions p</i>				
Deferred tax assets	34,924	15,956	-18,969	-54.3%
SUM NON-CURRENT ASSETS	225,086	208,223	-16,864	-7.5%
Inventories	86,676	122,404	35,728	41.2%
Trade receivables	40,841	55,712	14,871	36.4%
Financial assets		5,228	5,228	
Other receivables	16,454	19,743	3,289	20.0%
Income tax receivables	326	2,307	1,982	608.7%
Cash and cash equivalents	8,285	9,243	959	11.6%
Assets classified as held for sale				
Other assets				
SUM CURRENT ASSETS	152,581	214,638	62,056	40.7%
SUM ASSETS	377,667	422,860	45,193	12.0%

ALZCHEM GROUP (IN T€)	31.12.2021	31.12.2022	Deviation	
Share capital	101,763	101,763		
RETAINED EARNINGS (+) / LOSS (-)	101,127	121,044	19,916	19.7%
Other comprehensive income	-51,104	-15,316	35,788	-70.0%
Own shares	-1,009	-1,009		
SHARE TO THE SHAREHOLDERS	87,630	144,012	56,382	64.3%
Non-controlling interests	1,934	1,934		
SUM EQUITY	89,565	145,947	56,382	63.0%
Provisions for pensions	140,005	90,141	-49,864	-35.6%
Other provisions	24,372	17,011	-7,361	-30.2%
Loans	37,553	27,498	-10,055	-26.8%
Finance lease liabilities	5,793	4,622	-1,172	-20.2%
Trade liabilities				
Other liabilities	171	171		
Deferred tax liabilities	4,084	5,365	1,281	31.4%
SUM NON-CURRENT LIABILITIES	211,979	144,808	-67,171	-31.7%
Other provisions	2,968	1,944	-1,025	-34.5%
Loans	10,490	66,408	55,918	533.1%
Finance lease liabilities	1,805	1,707	-98	-5.4%
Finance liabilities				
Trade liabilities	32,780	37,386	4,606	14.1%
Other liabilities	26,220	23,060	-3,159	-12.0%
Income tax liabilities	1,862	1,602	-260	-14.0%
SUM CURRENT LIABILITIES	76,124	132,106	55,982	73.5%
Sum EQUITY AND LIABILITIES	377,667	422,860	45,193	12.0%

PENSION ACCOUNTING (IFRS)

Alzchem Group (M€)



- Adjustment of market interest rate from 1.0% → 3.7%; decreasing impact on provision
- Shift in expected pension trend from 2.0% to 2.25% (inflation expectations)
- Stable development of expected salary trend at 3.0%
- Moderately increasing cash payments

INCOME STATEMENT

Alzchem Group



ALZCHEM GROUP (IN T€)	Q1 2021	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Deviation (Q4)	
Revenue	104,321	111,000	95,920	111,052	129,395	140,435	139,193	133,200	22,148	20%
Increase (+) / Decrease (-) in inventories of finished goods	-2,144	-1,621	6,350	7,442	14,144	14,467	-1,959	-4,459	-11,901	-160%
Other income	3,983	2,505	2,143	2,729	4,070	5,736	5,955	8,416	5,687	208%
Raw materials and consumables used	-36,226	-37,538	-42,153	-54,753	-73,537	-74,027	-75,308	-66,006	-11,253	21%
Employee benefits expense	-33,038	-35,209	-30,875	-33,045	-34,000	-36,287	-31,316	-35,537	-2,492	8%
Other expense	-20,175	-20,143	-17,548	-20,932	-23,003	-32,517	-24,418	-21,198	-266	1%
EBITDA	16,722	18,993	13,838	12,493	17,070	17,807	12,149	14,416	1,923	15%
Depreciation expense	-5,771	-5,900	-6,206	-6,598	-6,305	-6,299	-6,324	-6,616	-18	0%
Impairment										
EBIT	10,951	13,094	7,632	5,895	10,765	11,508	5,825	7,800	1,905	32%
Investment income										
Other interest and similar income	512	244	139	-252	1,181	2,393	2,466	2,380	2,632	<-1.000
Other interest and similar expense	-425	-413	-431	-434	-603	-643	-753	-1,037	-603	139%
Financial result	88	-169	-292	-686	578	1,750	1,713	1,343	2,029	-296%
Result from associates										
Result from ordinary business	11,039	12,924	7,340	5,209	11,343	13,258	7,538	9,143	3,935	76%
Taxes on income and profit	-3,109	-3,710	-2,608	679	-3,603	-3,629	-1,559	-2,269	-2,948	-434%
<i>thereof income tax</i>	-2,737	-3,330	-1,944	-1,036	-2,520	-2,094	-842	562	1,598	-154%
<i>thereof change from deferred taxes</i>	-373	-380	-663	1,715	-1,082	-1,535	-717	-2,831	-4,545	-265%
Annual result	7,930	9,214	4,733	5,887	7,740	9,630	5,979	6,874	987	17%
<i>thereof minority interests</i>	43	43	43	43	43	43	43	43		
<i>thereof shares held by shareholders</i>	7,887	9,171	4,690	5,844	7,698	9,587	5,936	6,831	987	17%
Result per share in EUR	0.78 €	0.90 €	0.46 €	0.58 €	0.76 €	0.95 €	0.59 €	0.67 €		

INCOME STATEMENT

Alzchem Group



ALZCHEM GROUP (IN T€)

Revenue	
Increase (+) / Decrease (-) in inventories of finished goods and work in progress	
Other income	
Raw materials and consumables used	
Employee benefits expense	
Other expense	
EBITDA	
Depreciation expense	
Impairment	
EBIT	
Investment income	
Other interest and similar income	
Other interest and similar expense	
Financial result	
Result from associates	
Result from ordinary business	
Taxes on income and profit	
<i>thereof income tax</i>	
<i>thereof change from deferred taxes</i>	
Annual result	
<i>thereof minority interests</i>	
<i>thereof shares held by shareholders</i>	
Result per share in EUR	

Q4 2021	Q4 2022	Deviation (QoQ)	
111,052	133,200	22,148	19.9%
7,442	-4,459	-11,901	-159.9%
2,729	8,416	5,687	208.4%
-54,753	-66,006	-11,253	20.6%
-33,045	-35,537	-2,492	7.5%
-20,932	-21,198	-266	1.3%
12,493	14,416	1,923	15.4%
-6,598	-6,616	-18	0.3%
0	0	0	
5,895	7,800	1,905	32.3%
0	0	0	
-252	2,380	2,632	<-1.000%
-434	-1,037	-603	138.8%
-686	1,343	2,029	-295.7%
0	0	0	
5,209	9,143	3,935	75.5%
679	-2,269	-2,948	-434.3%
-1,036	562	1,598	-154.2%
1,715	-2,831	-4,545	-265.1%
5,887	6,874	987	16.8%
43	43	0	0.0%
5,844	6,831	987	16.9%
0.58 €	0.67 €	0	15.5%

YTD Dez.2021	YTD Dez.2022	Deviation (YoY)	
422,293	542,223	119,930	28.4%
10,028	22,193	12,166	121.3%
11,360	24,177	12,817	112.8%
-170,671	-288,877	-118,207	69.3%
-132,166	-137,139	-4,973	3.8%
-78,798	-101,136	-22,338	28.3%
62,046	61,441	-605	-1.0%
-24,475	-25,543	-1,069	4.4%
0	0	0	
37,572	35,898	-1,674	-4.5%
0	0	0	
643	8,421	7,778	>1.000%
-1,703	-3,036	-1,333	78.3%
-1,060	5,385	6,445	-608.0%
0	0	0	
36,512	41,282	4,771	13.1%
-8,748	-11,059	-2,311	26.4%
-9,047	-4,895	4,152	-45.9%
298	-6,165	-6,463	<-1.000%
27,763	30,223	2,460	8.9%
171	171	0	0.0%
27,592	30,052	2,460	8.9%
2.72 €	2.96 €	0	8.8%

CASHFLOW STATEMENT

Alzchem Group



CASHFLOW (IN M€)

	Q4 2021	Q4 2022	1 - 12 2021	1 - 12 2022
Consolidated earnings before taxes	5,209	9,143	36,512	41,282
Depreciation on fixed and intangible assets	6,598	6,616	24,475	25,543
Decrease in pension provisions	-344	-398	-1,419	-1,651
Loss (+) / Profit (-) from the sale of non-current assets	-40	-7	-50	-65
Other non-cash income (-) and expenses (+)	2,020	89	4,177	2,891
Financial result	686	-1,343	1,060	-5,385
Interests & Taxes	-1,249	-2,452	-7,341	-8,647
Increase (+) / Decrease (-) Net Working Capital	5,211	-1,789	-14,398	-58,208
Cashflow from ongoing operations (Net cash flow)	18,090	9,859	43,016	-4,240
Cash outflows for investments in fixed assets	-6,855	-6,325	-28,535	-29,068
Cash inflows from the sale of fixed assets	40	7	56	68
Cash inflows from the disposal of investments		5		489
Cashflow from investing activity	-6,815	-6,313	-28,479	-28,511
Free cashflow	11,275	3,546	14,537	-32,751
Deposits (+) / Repayment (-) bank loans long-term				
Repayment of bank loans long-term	-3,449	-2,514	-12,704	-10,490
Deposits (+) / Repayment (-) from short-term financing lines	-6,024	-604		56,353
Dividend payments			-7,821	-10,136
Payment of reduction in leasing liabilities	-497	-498	-1,911	-1,909
Payments for the acquisition of own shares (incl. transaction costs)			-1,013	
Payments to non-controlling interests			-171	-171
Cashflow from financing activity	-9,969	-3,616	-23,620	33,647
Net increase / decrease in cash and cash equivalents	1,307	-70	-9,083	896

SEGMENT OVERVIEW BY QUARTER

Alzchem Group



SALES

SALES	2020				2021				2022				Deviation PY (Q4)		YTD Q4 2022		Deviation PY (YOY)	
	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	T€	%	PY T€	Actual T€	T€	%
Basics & Intermediates	36,012	38,266	32,320	39,837	41,070	45,178	42,465	47,561	57,441	57,927	59,557	52,614	5,053	11%	176,274	227,539	51,265	29%
Specialty Chemicals	52,199	57,854	42,995	54,383	56,775	59,330	47,116	57,279	65,279	76,214	72,967	73,902	16,623	29%	220,499	288,362	67,863	31%
Other and Holding	6,529	6,391	6,058	6,414	6,477	6,492	6,339	6,212	6,675	6,294	6,670	6,684	472	8%	25,521	26,323	802	3%
Group Consolidation																		
Alzchem Group	94,740	102,511	81,373	100,634	104,321	111,000	95,920	111,052	129,395	140,435	139,193	133,200	22,148	20%	422,293	542,223	119,930	28%

EBITDA

EBITDA	2020				2021				2022				Deviation PY (Q4)		YTD Q4 2022		Deviation PY (YOY)	
	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	T€	%	PY T€	Actual T€	T€	%
Basics & Intermediates	1,903	2,485	2,006	2,587	2,791	3,826	3,118	1,250	2,841	853	-2,621	3,910	2,659	213%	10,985	4,983	-6,002	-55%
Specialty Chemicals	10,158	14,457	9,418	10,092	13,947	14,801	10,096	11,820	14,267	16,322	14,637	7,789	-4,031	-34%	50,664	53,014	2,350	5%
Other and Holding	317	81	361	230	435	-43	512	502	-139	830	1,038	230	-272	-54%	1,405	1,959	554	39%
Group Consolidation	-63	-201	202	-227	-451	409	112	-1,079	103	-200	-905	2,487	3,567	330%	-1,008	1,485	2,494	-247%
Alzchem Group	12,315	16,822	11,986	12,683	16,722	18,993	13,838	12,493	17,072	17,805	12,149	14,416	1,923	15%	62,046	61,441	-605	-1%

EXECUTIVE TEAM

Alzchem Group AG



ANDREAS NIEDERMAIER

CEO

BEI ALZCHEM SEIT 1999

RESSORTVERANTWORTUNG

Finanzen & Controlling,
Unternehmensstrategie, Investor
Relations & Kommunikation, Risk
Management, Personal, IT, Supply
Chain Management,
Recht/Patente & Marken

DR. GEORG WEICHSELBAUMER

CSO

BEI ALZCHEM SEIT 2012

RESSORTVERANTWORTUNG

Marketing, Vertrieb,
Innovationsmanagement &
Verfahrensentwicklung, F&E,
Produktsicherheit /-zulassung

KLAUS ENGLMAIER

COO

BEI ALZCHEM SEIT 1988

RESSORTVERANTWORTUNG

Produktion, Engineering,
Umweltschutz/Sicherheit/Ges
undheit/Qualität, Technik

ALZCHEM GROUP LOCATIONS


Production sites and sales companies



"VERBUND" – FULLY INTEGRATED BUSINESS MODEL



Benefits of the "Verbund" system approach



BENEFITS OF "VERBUND"

- Full control of product quality and specifications
- Lower costs
- Higher financial predictability
- Certainty of supply
- Well positioned to address niche markets
- Economies of scale
- Low carbon footprint

MEGATRENDS AS GROWTH DRIVERS



POPULATION
GROWTH



LONGER LIFE
EXPECTANCY



CLIMATE
CHANGE



SUSTAINABILITY

OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries







	MAIN PRODUCTS	DESCRIPTION	END-MARKETS
SPECIALTY CHEMICALS	CREAMINO®	A feed additive for broilers and pigs	Feed additive
	Creapure®	Premium brand for creatine monohydrate as a food supplement in sports nutrition	Food supplements
	LIVADUR	Dietary supplement with pure creatine	Food supplements
	Dormex®	Plant growth regulator used in fruit production	Agriculture
	BREATHRU'S 301	Additive for plant protection formulations	Agriculture
	Sitofex®	Plant growth regulator used in fruit production	Agriculture
	Alzogur®	Biocide for the prevention of diseases in animal production	Agriculture
	Silzot HQ	Silicon nitride powder for ceramic applications	Ceramics
	Bioselect®	Highly purified form of guanidine salts	Pharmaceuticals / API
	Cyanamide	An organic compound widely used in agriculture and pharmaceuticals	Agriculture and pharmaceuticals
	DYHARD®	Hardeners and accelerators in powder, paste and liquid form	Hardener & Accelerator Systems for Composite Materials
	Thiourea	Various applications incl. flotation agents and pharmaceutical raw materials	Mining and pharmaceuticals
	Nitroguanidine	Intermediates for agrochemical products	Various

OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries



	MAIN PRODUCTS	DESCRIPTION	END-MARKETS
BASICS & INTERMEDIATES		Calcium carbide-based mixtures for hot metal desulphurization	Steel industry
	Guanidine Salts	Fuel for airbags, key production of the intermediate product	Automotive
	Dicyandiamide	Versatile intermediate in various markets including the pharmaceutical industry	Pharmaceutical Agriculture
		Business fields in color, agro and pharmaceutical applications	Pigments Pharmaceutical
		Reduction of methane emissions during storage of manure	Agriculture
		Special calcium cyanamide multi-effect fertilizer	Agriculture
OTHER & HOLDING	Operation of the Trostberg Chemical Park (companies located at the site: Alzchem, BASF, MBCC Group, Firmenich, Aramark, VIACTIV)		
	Site services		
	Other activities not included in the "Specialty Chemicals" or "Basics & Intermediates" segments		

KEY SHARE DATA

Share Details as of February 24, 2023



SHARES OUTSTANDING	10,176,335 including 40,581 shares held by Alzchem Group AG
--------------------	---

LAST CLOSING PRICE	EUR 18.85
--------------------	-----------

MARKET CAPITALIZATION	EUR 191.8 m
-----------------------	-------------

TICKER	ACT
--------	-----


WKN	A2YNT3
-----	--------

ISIN	DE000A2YNT30
------	--------------

LISTING	Frankfurt Stock Exchange – Prime Standard
---------	--

DESIGNATED SPONSOR	Baader Bank AG Oddo Seydler Bank AG
--------------------	--

SHAREHOLDER STRUCTURE



As of February 2023. The information on the shareholders is based on the figures reported to us by them. Data regarding the free float are provided in accordance with section 2.3 of the “Guide to the DAX Equity Indices, i.e. considering the number of 40,581 own shares currently held by the company.”